Deutsche Bank’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-149,327
| Closed | -$7.87M | – | 3845 |
|
|
2026
Q1 | $7.87M | Sell |
149,327
-252,119
| -63% | -$10.4M | ﹤0.01% | 1131 |
|
|
2025
Q4 | $16.2M | Buy |
401,446
+20,697
| +5% | +$478K | 0.01% | 932 |
|
|
2025
Q3 | $2.86M | Buy |
380,749
+7,502
| +2% | +$47.9K | ﹤0.01% | 1572 |
|
|
2025
Q2 | $1.39M | Sell |
373,247
-12,230
| -3% | -$38.2K | ﹤0.01% | 1909 |
|
|
2025
Q1 | $1.06M | Sell |
385,477
-12,902
| -3% | -$52.7K | ﹤0.01% | 2121 |
|
|
2024
Q4 | $2.21M | Sell |
398,379
-144,467
| -27% | -$978K | ﹤0.01% | 1786 |
|
|
2024
Q3 | $4.53M | Buy |
542,846
+445,668
| +459% | +$3.67M | ﹤0.01% | 1314 |
|
|
2024
Q2 | $662K | Buy |
97,178
+73,526
| +311% | +$445K | ﹤0.01% | 2203 |
|
|
2024
Q1 | $155K | Buy |
23,652
+664
| +3% | +$4.34K | ﹤0.01% | 2966 |
|
|
2023
Q4 | $149K | Buy |
22,988
+539
| +2% | +$2.85K | ﹤0.01% | 3026 |
|
|
2023
Q3 | $113K | Buy |
22,449
+4,121
| +22% | +$26.2K | ﹤0.01% | 3107 |
|
|
2023
Q2 | $160K | Buy |
+18,328
| New | +$214K | ﹤0.01% | 3020 |
|
|
2022
Q2 | – | Sell |
-8,033
| Closed | -$24K | – | 4320 |
|
|
2022
Q1 | $24K | Sell |
8,033
-878
| -10% | -$3.75K | ﹤0.01% | 4030 |
|
|
2021
Q4 | $63K | Buy |
8,911
+440
| +5% | +$3.66K | ﹤0.01% | 3887 |
|
|
2021
Q3 | $88K | Buy |
8,471
+2,577
| +44% | +$26.7K | ﹤0.01% | 3944 |
|
|
2021
Q2 | $72K | Buy |
5,894
+408
| +7% | +$6.95K | ﹤0.01% | 4234 |
|
|
2021
Q1 | $121K | Buy |
+5,486
| New | +$120K | ﹤0.01% | 3879 |
|
Other funds holding TERN
Deutsche Bank's TERN Position: Q2 2026 in Review
Deutsche Bank sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 149,327 shares — an estimated $7.87M sold.
Deutsche Bank first reported a position in TERN in Q1 2021 and held it in 17 quarters. The position peaked at $16.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Deutsche Bank reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Deutsche Bank sold 149,327 Terns Pharmaceuticals shares in Q2 2026, an estimated $7.87M.
- Deutsche Bank first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 17 quarters.
- Deutsche Bank's Terns Pharmaceuticals position peaked at $16.2M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.